Gus A Baker1, Rebecca L Bromley2, Maria Briggs1, Christopher P Cheyne1, Morris J Cohen1, Marta García-Fiñana1, Alison Gummery1, Rachel Kneen1, David W Loring1, George Mawer1, Kimford J Meador1, Rebekah Shallcross1, Jill Clayton-Smith1. 1. From the Departments of Molecular and Clinical Pharmacology (G.A.B.), Biostatistics (C.P.C., M.G.-F.), and Clinical Psychology (R.S.), Institute of Infection and Global Health (M.J.C., A.G.), and Alder Hey Children's Hospital & Institute of Infection & Global Health (R.K.), University of Liverpool; Institute of Human Development (R.L.B., J.C.-S.), University of Manchester; Manchester Academic Health Sciences Centre (R.L.B., M.B., G.M., J.C.-S.), Central Manchester University Hospitals Foundation Trust, UK; Department of Neurology (M.J.C.), Georgia Regents University, Augusta; Department of Neurology & Pediatrics (D.W.L.), Emory University, Atlanta, GA; and Department of Neurology & Neurological Sciences (K.J.M.), Stanford University, CA. 2. From the Departments of Molecular and Clinical Pharmacology (G.A.B.), Biostatistics (C.P.C., M.G.-F.), and Clinical Psychology (R.S.), Institute of Infection and Global Health (M.J.C., A.G.), and Alder Hey Children's Hospital & Institute of Infection & Global Health (R.K.), University of Liverpool; Institute of Human Development (R.L.B., J.C.-S.), University of Manchester; Manchester Academic Health Sciences Centre (R.L.B., M.B., G.M., J.C.-S.), Central Manchester University Hospitals Foundation Trust, UK; Department of Neurology (M.J.C.), Georgia Regents University, Augusta; Department of Neurology & Pediatrics (D.W.L.), Emory University, Atlanta, GA; and Department of Neurology & Neurological Sciences (K.J.M.), Stanford University, CA. rebecca.bromley@manchester.ac.uk.
Abstract
OBJECTIVE: To delineate the risk to child IQ associated with frequently prescribed antiepileptic drugs. METHODS: Children born to women with epilepsy (n = 243) and women without epilepsy (n = 287) were recruited during pregnancy and followed prospectively. Of these, 408 were blindly assessed at 6 years of age. Maternal and child demographics were collected and entered into statistical models. RESULTS: The adjusted mean IQ was 9.7 points lower (95% confidence interval [CI] -4.9 to -14.6; p < 0.001) for children exposed to high-dose (>800 mg daily) valproate, with a similar significant effect observed for the verbal, nonverbal, and spatial subscales. Children exposed to high-dose valproate had an 8-fold increased need of educational intervention relative to control children (adjusted relative risk, 95% CI 8.0, 2.5-19.7; p < 0.001). Valproate at doses <800 mg daily was not associated with reduced IQ, but was associated with impaired verbal abilities (-5.6, 95% CI -11.1 to -0.1; p = 0.04) and a 6-fold increase in educational intervention (95% CI 1.4-18.0; p = 0.01). In utero exposure to carbamazepine or lamotrigine did not have a significant effect on IQ, but carbamazepine was associated with reduced verbal abilities (-4.2, 95% CI -0.6 to -7.8; p = 0.02) and increased frequency of IQ <85. CONCLUSIONS: Consistent with data from younger cohorts, school-aged children exposed to valproate at maternal doses more than 800 mg daily continue to experience significantly poorer cognitive development than control children or children exposed to lamotrigine and carbamazepine.
OBJECTIVE: To delineate the risk to child IQ associated with frequently prescribed antiepileptic drugs. METHODS:Children born to women with epilepsy (n = 243) and women without epilepsy (n = 287) were recruited during pregnancy and followed prospectively. Of these, 408 were blindly assessed at 6 years of age. Maternal and child demographics were collected and entered into statistical models. RESULTS: The adjusted mean IQ was 9.7 points lower (95% confidence interval [CI] -4.9 to -14.6; p < 0.001) for children exposed to high-dose (>800 mg daily) valproate, with a similar significant effect observed for the verbal, nonverbal, and spatial subscales. Children exposed to high-dose valproate had an 8-fold increased need of educational intervention relative to control children (adjusted relative risk, 95% CI 8.0, 2.5-19.7; p < 0.001). Valproate at doses <800 mg daily was not associated with reduced IQ, but was associated with impaired verbal abilities (-5.6, 95% CI -11.1 to -0.1; p = 0.04) and a 6-fold increase in educational intervention (95% CI 1.4-18.0; p = 0.01). In utero exposure to carbamazepine or lamotrigine did not have a significant effect on IQ, but carbamazepine was associated with reduced verbal abilities (-4.2, 95% CI -0.6 to -7.8; p = 0.02) and increased frequency of IQ <85. CONCLUSIONS: Consistent with data from younger cohorts, school-aged children exposed to valproate at maternal doses more than 800 mg daily continue to experience significantly poorer cognitive development than control children or children exposed to lamotrigine and carbamazepine.
Authors: Petra Bittigau; Marco Sifringer; Kerstin Genz; Ellen Reith; Dana Pospischil; Suresh Govindarajalu; Mark Dzietko; Stefanie Pesditschek; Ingrid Mai; Krikor Dikranian; John W Olney; Chrysanthy Ikonomidou Journal: Proc Natl Acad Sci U S A Date: 2002-11-04 Impact factor: 11.205
Authors: N Adab; U Kini; J Vinten; J Ayres; G Baker; J Clayton-Smith; H Coyle; A Fryer; J Gorry; J Gregg; G Mawer; P Nicolaides; L Pickering; L Tunnicliffe; D W Chadwick Journal: J Neurol Neurosurg Psychiatry Date: 2004-11 Impact factor: 10.154
Authors: E Gaily; E Kantola-Sorsa; V Hiilesmaa; M Isoaho; R Matila; M Kotila; T Nylund; A Bardy; E Kaaja; M-L Granström Journal: Neurology Date: 2004-01-13 Impact factor: 9.910
Authors: J I Morrow; S J Hunt; A J Russell; W H Smithson; L Parsons; I Robertson; R Waddell; B Irwin; P J Morrison; J J Craig Journal: J Neurol Neurosurg Psychiatry Date: 2008-10-31 Impact factor: 10.154
Authors: H H Ardinger; J F Atkin; R D Blackston; L J Elsas; S K Clarren; S Livingstone; D B Flannery; J M Pellock; M J Harrod; E J Lammer Journal: Am J Med Genet Date: 1988-01
Authors: Kimford J Meador; Page B Pennell; Ryan C May; Carrie A Brown; Gus Baker; Rebecca Bromley; David W Loring; Morris J Cohen Journal: Neurology Date: 2019-12-23 Impact factor: 9.910